SEBI Reg. Investment Advisor

Download App

MoneyWorks4Me

Venus Remedies jumps on securing marketing authorizations for Docetaxel in Israel, Cytarabine in Colombia

21 Dec 2023 Evaluate

Venus Remedies is currently trading at Rs. 400.00, up by 24.05 points or 6.40% from its previous closing of Rs. 375.95 on the BSE.

The scrip opened at Rs. 375.95 and has touched a high and low of Rs. 407.60 and Rs. 371.30 respectively. So far 42911 shares were traded on the counter.

The BSE group 'B' stock of face value Rs. 10 has touched a 52 week high of Rs. 419.05 on 07-Dec-2023 and a 52 week low of Rs. 145.00 on 08-Feb-2023.

Last one week high and low of the scrip stood at Rs. 401.30 and Rs. 371.40 respectively. The current market cap of the company is Rs. 537.35 crore.

The promoters holding in the company stood at 41.76%, while Institutions and Non-Institutions held 1.03% and 57.21% respectively.

Venus Remedies has secured marketing authorizations for three variants of Docetaxel in Israel and Cytarabine 100MG in Colombia. The approved Docetaxel variants (160MG/8ML, 80MG/4ML, 20MG/1ML) and Cytarabine further solidify its commitment to advancing healthcare solutions globally.

Earlier, the company had unveiled a significant transformation of its consumer healthcare division, R3SET. This strategic pivot marks R3SET's foray into the wellness arena, coupled with the expansion of its pain management portfolio, showcasing the company's holistic approach to wellness solutions.

enus Remedies is one of the handful player in pharmaceutical sector to launch world global injectable manufacturers.

Venus Remedies Share Price

1042.35 3.25 (0.31%)
17-Apr-2026 16:59 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1675.20
Dr. Reddys Lab 1235.40
Cipla 1238.30
Zydus Lifesciences 942.55
Lupin 2324.25
View more..

About MoneyWorks4Me

MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.

Our Vision

To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.

What Makes MoneyWorks4Me Different

Our Approach: Ensuring compounding work its magic on client portfolio.

MoneyWorks4Me ensures this through:

×